ACTRN12617000911392已完成1 期
A Phase I, Randomized, Double blinded, Adaptive, Single and Multiple Ascending Dose Study of the Safety and Tolerability of NPI 001 Solution in Healthy Subjects
acuity Pharmaceuticals Pty Ltd0 个研究点目标入组 54 人开始时间: 2017年6月21日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
Unknown
2 期
Safety, Pharmacokinetics, Pharmacodynamics and Efficacy study of MRG-001 on Severe and Critical SARS-CoV-2CTRI/2022/01/039274Medregen LLC
已完成
2 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with PD-L1 positive recurrent or metastatic HNSCCJPRN-jRCT2080225258600
已完成
2 期
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (study 209229)NL-OMON52820GlaxoSmithKline25
进行中（未招募）
1 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2019-002263-99-HUGlaxoSmithKline Research & Development Ltd600
进行中（未招募）
1 期
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerEUCTR2019-002263-99-NOGlaxoSmithKline Research & Development Ltd315